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3:HUL.InstRepos:dash.current.terms-of-use#LAAEvidence of successful management of multidrug-
resistant tuberculosis (MDRTB) is mainly generated from
referral hospitals in high-income countries. We evaluate the
management of MDRTB in 5 resource-limited countries:
Estonia, Latvia, Peru, the Philippines, and the Russian
Federation. All projects were approved by the Green Light
Committee for access to quality-assured second-line drugs
provided at reduced price for MDRTB management. Of
1,047 MDRTB patients evaluated, 119 (11%) were new,
and 928 (89%) had received treatment previously. More
than 50% of previously treated patients had received both
first- and second-line drugs, and 65% of all patients had
infections that were resistant to both first- and second-line
drugs. Treatment was successful in 70% of all patients, but
success rate was higher among new (77%) than among
previously treated patients (69%). In resource-limited set-
tings, treatment of MDRTB provided through, or in collabo-
ration with, national TB programs can yield results similar to
those from wealthier settings.
M
ultidrug-resistant tuberculosis (MDRTB), defined as
TB resistant to at least isoniazid and rifampin, repre-
sents an obstacle to TB control, especially in areas where
MDRTB prevalence is high (1). New World Health
Organization (WHO) estimates suggest that 424,203
MDRTB cases occurred in 2004 (95% confidence interval
376,019–620,061), or 4.3% of all new and previously
treated TB cases. More than half of the estimated MDRTB
cases were in China and India, while the highest estimated
prevalences were in countries of the former Soviet Union
and certain provinces of China (2).
DOTS is the internationally recommended strategy for
TB control and is based on a 6-month treatment regimen
with first-line drugs (isoniazid, rifampin, pyrazinamide,
and ethambutol) for new patients and an 8-month treat-
ment regimen with isoniazid, rifampin, pyrazinamide,
ethambutol, and streptomycin for re-treatment patients (3).
While DOTS prevents the emergence of drug resistance in
drug-susceptible cases, in patients with MDRTB, this
treatment yields inadequate cure rates (4–7). A retrospec-
tive cohort study of treatment of MDRTB with this regi-
men in 6 countries showed treatment success rates of 52%
(range 11%–60%) in new cases and 29% (range
18%–36%) in previously treated cases (5). In addition, the
frequency of TB recurrence among MDRTB patients pre-
viously considered to be cured after this treatment has been
reported at 28% (6). Treating MDRTB with second-line
drugs may cure >65% of patients and stop ongoing trans-
mission (8–10). However, most of the evidence of success-
ful MDRTB management is generated from high-income
countries where treatment is provided in referral hospitals
(10).
In 1999, WHO and partner agencies launched DOTS-
Plus to manage MDRTB in resource-limited settings, a
term that was recently abolished since it was used for the
piloting of the management of MDRTB within the context
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these areas to address the complexities associated with
treating MDRTB (11). As part of this strategy, a novel part-
nership known as the Green Light Committee (GLC) was
created to foster access to, and rational use of, second-line
drugs (11–13). The second-line drugs included in the
WHO Model List of Essential Medicines are amikacin,
capreomycin, ciprofloxacin, cycloserine, ethionamide,
kanamycin, levofloxacin, ofloxacin, p-aminosalicylic acid,
and prothionamide (11). GLC reviews applications from
projects that wish to integrate MDRTB management into a
DOTS-based TB control program. If the applicant propos-
es a strategy consistent with international recommenda-
tions and agrees to the monitoring procedures of GLC,
then access to reduced-price, quality-assured second-line
drugs is granted. Some of the requirements for GLC
endorsement include a well-functioning DOTS program,
long-term political commitment, rational case-finding
strategies, diagnosis of MDRTB through quality-assured
culture and drug susceptibility testing (DST), treatment
strategies that use second-line drugs under proper manage-
ment conditions, uninterrupted supply of quality-assured
second-line drugs, and a recording and reporting system
designed for MDRTB control programs that enables mon-
itoring and evaluation of program performance and treat-
ment outcome (11,13,14). These conditions represent the
MDRTB control framework. Projects must be tailored to
site-specific epidemiologic and programmatic conditions
within this framework. As a result, MDRTB control pro-
grams may differ substantially between settings (11). Some
aspects in which MDRTB control programs may vary
include whether all TB patients are tested with culture and
DST or only patients with an increased risk for MDRTB,
use of standardized or individualized second-line treat-
ment regimen, and hospitalization of MDRTB patients or
provision of treatment on an ambulatory basis. This analy-
sis of the first 5 GLC-endorsed MDRTB control programs
provides, for the first time, results on management of
MDRTB under DOTS-based program conditions in multi-
ple resource-limited countries by using standardized treat-
ment outcome definitions.
Methods
This is a study of MDRTB patients enrolled in Estonia,
Latvia, Lima (Peru), Manila (the Philippines), and Tomsk
Oblast (Russian Federation). The data were collected
prospectively. The enrollment period started in 1999 for
Lima and Manila, 2000 for Latvia and Tomsk, and 2001
for Estonia and ended December 31, 2001. All patients
evaluated were managed under GLC-approved protocols
and had the opportunity to receive >24 months of treat-
ment. In addition, follow-up data on successfully treated
patients were collected at the beginning of 2006, two years
after the last patient’s treatment ended (December 31,
2003).
A new MDRTB patient was defined as a patient who
had never received TB treatment or who had received TB
treatment for <1 month. An MDRTB patient previously
treated with only first-line drugs was defined as an
MDRTB patient who had been treated for >1 month with
only first-line anti-TB drugs. An MDRTB patient previ-
ously treated with second-line drugs was defined as an
MDRTB patient who had been treated for >1 month with
>1 second-line anti-TB drug (with or without first-line
drugs). Six standard and mutually exclusive categories
were used to define treatment outcome: cure, treatment
completed, death, default, failure, and transfer out (14)
(Table 1). The treatment success percentage was obtained
by adding the percentage of cured patients to the percent-
age of patients who completed treatment.
Outcome data were recorded by the individual projects
in centralized electronic registers. International standards
for core data collection in MDRTB control programs were
developed in 2000 (11). Projects developed their own stan-
dardized forms and electronic databases that included all
of the core data elements. Aggregated program and patient
data were collected from each project with a data collec-
tion form developed by GLC. The accuracy of laboratory
methods was verified though regular quality assurance
exercises performed by a network of WHO/International
Union Against Tuberculosis and Lung Disease suprana-
tional TB reference laboratories, as previously described
(1). For each project, data submitted to WHO were
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discrepancies were corrected in consultation with the pro-
ject’s investigators.
Statistical tests were performed with the Fisher exact
test for 2×2 comparisons and the χ2 test for the other
tables. For all statistical tests, we regarded a p value <0.05
as significant. Data were analyzed in Stata version 8
(StataCorp LP, College Station, TX, USA).
Results
The 5 programs are described in Table 2. All projects
are conducted in well-established DOTS programs. Four
projects are integrated into the national TB program
(NTP): Estonia, Latvia, Lima, and Tomsk. The project in
Manila is conducted by a nongovernmental organization at
a private tertiary hospital, in close collaboration with NTP.
All projects provide free care to MDRTB patients. The
programs in Estonia, Latvia, and Tomsk are the only avail-
able treatment options for MDRTB, while in Lima and
Manila, treatment in the private sector is also available.
In all projects, financing is obtained through both
national healthcare budgets and external sources. All proj-
ects work in collaboration with technical agencies and, in
Lima and Tomsk, nongovernmental organizations.
Directly observed treatment (DOT) is standard care in all
projects. Treatment is observed by a range of persons,
including healthcare workers (primarily nurses) and com-
munity volunteers. DOT worker incentives are provided
in Estonia, Lima, and Tomsk, primarily consisting of
money (Estonia) and food and money (Lima and Tomsk).
Patient incentives, food and free transportation, are pro-
vided in all projects except for those in Manila. In Lima,
patients also receive housing and social, educational, and
financial support, as needed. Lima and Manila offer
patient support groups. Sputum culture and DST to first-
and second-line drugs are performed at each project site
except for Lima and Tomsk, which rely on an internation-
al laboratory for DST to second-line drugs. All projects
test for susceptibility to several first- and second-line
drugs. In 3 projects, those in Estonia, Latvia, and Tomsk,
MDRTB patients are hospitalized in a separate ward or
building until they are noninfectious. In Peru and Manila,
only severely ill patients and patients with side effects are
hospitalized.
The 5 projects use different case-finding strategies and
treatment options (use of empiric treatment regimens
while awaiting DST results or not) (Table 2). In Estonia,
Latvia, and Tomsk, all (new and previously treated)
patients received DST at the start of treatment. However,
in this study MDRTB patients from Tomsk were all previ-
ously treated patients on a waiting list for treatment. In
Lima, DST is only performed on isolates from patients in
whom treatment failed or suspicion of MDRTB is high.
Most patients in Lima were referred to the GLC-approved
MDRTB control program only after failure of a standard-
ized regimen, which contained second-line drugs and was
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of treatment histories; most came after failure of treatment
provided by private physicians outside the DOTS program.
Because of the long turnaround times for DST results from
the international laboratory, patients in Lima and Tomsk
often received empiric treatment after culture conversion.
For each program, the drugs against which the strains were
tested are given in Table 2; however, not all strains were
tested against all the drugs listed for each program.
All projects used DST results and previous treatment
history to design the individualized regimen. Across the 5
projects, regimens contained >4 drugs, and most patients
received >4 drugs initially. All regimens included an
injectable agent (amikacin, capreomycin, kanamycin, or
streptomycin) and a fluoroquinolone (ciprofloxacin, lev-
ofloxacin, or ofloxacin). Nearly all drugs were adminis-
tered for the duration of treatment except for the injectable
agent, which was given for a specified interval after the
patient’s specimens were culture negative. Treatment dura-
tion was 18–24 months, and the exact length was usually
determined individually for each patient. The frequency of
drugs used in the regimens is shown in Table 3. The medi-
an duration of patient follow-up after a patient’s having
been declared cured or treatment completed was 24
months (range 12 months [Lima and Tomsk] to 36 months
[Estonia]).
Drugs were administered under direct observation. In
Lima, Tomsk, and Manila, drugs were administered 6 days
per week; in Estonia and Latvia, drugs were given 7 days
during the hospital phase and then 5 or 6 days a week after
discharge. Monitoring of treatment regimens was based on
the results of monthly sputum smear and culture. Chest
radiographs were also performed every 3 months in
Estonia, Latvia, and Tomsk and every 6 months in Lima
and Manila. All projects except that in Manila had access
to adjunctive surgery for major interventions such as lung
resection. Each project provided patients with ancillary
drugs to manage adverse events.
MDRTB program cohort characteristics are shown in
Table 4. Among 1,047 MDRTB patients, 119 (11%) were
new, and 928 (89%) were previously treated. Among the
919 previously treated patients from whom details could
be obtained, 438 (48%) had received only first-line drugs
and 481 (52%) first and second-line drugs. Few patients’
isolates were resistant to only rifampin and isoniazid
(2.6%); most (65%) were resistant to first- and second-line
drugs. HIV coinfection was identified in 0% (Estonia and
Tomsk) and 4.5% (Latvia) of patients. (In Lima and
Tomsk, all MDRTB patients were tested for HIV; in
Estonia and Latvia, 67% and 90% of MDRTB patients
were tested; and in Manila HIV testing was not per-
formed.) Frequency of hospitalization varied from 5.0%
(Manila) to 100% (Latvia), and duration of hospitalization
ranged from 29 days (Manila) to 267 days (Tomsk).
The treatment outcomes of new, previously treated, and
all MDRTB patients are shown in Table 5 and Figure 1.
Treatment was successful in 70% of 1,047 patients (range
59%–83%). Failure occurred in 3.3% to 11% of patients,
default in 6.3% to 16%, and death in 3.7% to 19%. In
Estonia and Latvia, MDRTB patients not previously treat-
ed for TB had a higher treatment success rate (80% vs.
61%, odds ratio [OR] 2.54, 95% confidence interval [CI]
1.47–4.37, p<0.005) and a lower failure rate (4.4% vs.
15%, OR 0.26, 95% CI 0.10–0.67, p<0.005) than previous-
ly treated patients. Adverse events led to treatment cessa-
tion in 3.2% of patients (range 0% [Tomsk] to 8.6%
[Manila]). By the end of 2005, a total of 14 of 670 patients
(2.1%) who were followed-up after cure or treatment com-
pletion had relapsed (range 1.1% [Lima] to 10.0%
[Estonia]) (Table 6).
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Today, management of MDRTB is included as a recom-
mended part of the new Stop TB Strategy (15). WHO’s
guidelines have also been revised to encourage countries to
collect drug resistance surveillance data from patients in
different retreatment categories and to build capacity to
diagnose and treat MDRTB within the context of DOTS
(16). However, few NTPs in resource-limited settings have
integrated effective treatment strategies for resistant cases
(17).
The major perceived barrier to MDRTB treatment is the
high cost of quality-assured second-line drugs. Additional
MDRTB Management in Resource-limited Settings
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requirements, adverse events associated with second-line
drugs, low availability of quality-assured second-line
drugs, difficulties in ensuring adequate patient support
(including DOT) during the long treatment course, and the
risk for resistance to second-line drugs (18,19).
Consequently, many NTPs focus on achieving high cure
rates in their DOTS programs and neither diagnose nor
treat MDRTB (17).
This study represents the first multicountry evaluation
of MDRTB patients treated in resource-limited settings
under the GLC mechanism and endorsed by the respective
NTPof each country. Although program design and patient
management varied, the results show that treating MDRTB
in resource-limited settings is feasible and effective.
Treatment with second-line drugs is more successful than
a 6- to 8-month regimen of first-line drugs for such
patients and, in spite of a patient population characterized
by high proportions of severe chronic cases with extensive
resistance patterns, treatment outcomes of these projects
match the outcomes of treatment with second-line drugs in
wealthier settings (10). However, in each project, exten-
sive training on managerial, laboratory, clinical, and social
aspects of MDRTB control took place before GLC
approval and initiation of treatment. Socioeconomic sup-
port was provided to the patients in 4 of the 5 sites, and in
all sites a patient-centered approach was used for treatment
delivery, with DOT ensured during the full course of treat-
ment. These efforts may partly explain why the relapse
rates were low (2.1%) and suggest such best practices are
essential for a successful outcome. In addition, all projects
were supported by technical agencies, and some benefited
from extensive NGO support.
Significant differences were seen in favorable (cure and
completed) and unfavorable (default, failure, died, and
transferred out) outcomes between projects (p = 0.002),
and although patient populations cannot be compared
between projects as a result of different TB epidemiologic
features in different countries, some general observations
can be made with respect to the differences in treatment
outcomes. Default rates were higher in Estonia, Latvia,
and Manila than in Lima and Tomsk. TB specialists in
Estonia and Latvia attributed the high default rates to a
high proportion of patients with severe alcohol abuse dis-
orders for whom adherence to treatment is difficult. A
recent study in Latvia could not confirm that alcohol mis-
use was clearly linked to default, but the number of nonad-
herent patients was small and the statistical power
correspondingly weak (9). Although the project in Tomsk
also experienced problems with alcoholism, default rates
were low because a large proportion of patients were
imprisoned (41%) during the treatment period. The high
default rate in Manila appeared to be related to the facts
that at the beginning of Manila’s project, treatment was
delivered in a single site that was not easily accessible to
all patients and that drugs to manage adverse reactions had
to be purchased by the patients. In addition, during the
reporting period, the program in Manila did not provide
any patient or DOT worker incentives. The low default
RESEARCH
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Figure 1. Treatment outcomes of multidrug-resistant tuberculosis
patients in Estonia (46 patients), Latvia (245 patients), Lima (508
patients), Manila (105 patients), and Tomsk (143 patients).rates in Lima and Tomsk could be attributed to a large vari-
ety of treatment delivery options and incentive and enabler
programs for patients.
The high frequency of death in Lima likely reflects the
fact that in a high proportion of patients, a standard
MDRTB treatment regimen with second-line drugs was
unsuccessful (20). The proportion of patients previously
treated with second-line drugs was much higher in Lima
(75%) than in other projects (14%–45%) (Figure 2).
However, the proportions of patients with infections resist-
ant to first- and second-line drugs were similar in Latvia,
Lima, Manila, and Tomsk (p = 0.47). In Estonia, resistance
patterns to first- and second-line drugs differed substantial-
ly when compared with patterns in the other 4 projects
(p<0.0001), and in Estonia all patients had infections
resistant to first- and second-line drugs (Table 4).
During the study period, only Estonia and Latvia rou-
tinely attempted to identify MDRTB patients at the start of
their first treatment for TB, and the results show that early
identification and referral may reduce death and treatment
failure and thus improve treatment success. This finding is
consistent with those of Turett et al. (21). The delay in the
diagnosis of MDRTB results in treatment of patients with
chronic disease, progressive parenchymal destruction,
higher bacillary loads, and continuing transmission (22).
The study confirms that adverse events are manageable
in the treatment of MDRTB in resource-limited settings.
Few patients stopped treatment because of adverse events,
which is similar to a previous report. Each project, howev-
er, applied intensive approaches to manage adverse events,
including altering dosages when appropriate, administer-
ing ancillary drugs to treat adverse events, and discontinu-
ing drugs. In addition, all projects conducted special
training on adverse events to second-line drugs and used
standard protocols for their registration (23).
Studies of the cost and cost-effectiveness of MDRTB
management have been completed in Estonia (unpub.
data), Manila (24), and Tomsk (25). From the health sys-
tem perspective, the average cost per patient treated was
approximately US $3,400 in the Philippines and US
$9,000–$10,000 in Estonia and Tomsk. The higher costs in
Estonia and Tomsk reflect considerable hospitalization
during treatment (30%–50% of overall costs compared to
3% in the Philippines). The second-line drug costs ranged
from US $1,600 in the Philippines to US $3,700 in Tomsk;
second-line drugs were the highest cost items in the
Philippines and Tomsk and the second highest in Estonia.
Our study has several limitations. First, risk factors for
poor treatment outcomes could not be examined because
data were in an aggregate form, not as individual patient
data. The second limitation is that the results are not repre-
sentative of all GLC-approved projects currently function-
ing. As mentioned, GLC projects are tailored to the local
health infrastructure, human and financial resources, and
the epidemiologic situation. As a result, costs and out-
comes differ between projects. Several projects have been
approved by GLC that use standardized treatment regi-
mens based on representative drug resistance surveillance
data in relevant patient categories. In settings without a
history of second-line drug use, MDRTB control is likely
to yield better treatment outcome results. In these settings,
susceptibility to the most effective second-line drugs may
be preserved, permitting perhaps shorter regimens with
fewer, less toxic drugs. As all GLC-approved MDRTB
control projects record the same core data, information on
success within each of the different approaches will be
available within the next 3 years.
Conclusion
After successful piloting of MDRTB management
within TB control programs, WHO and partners have
reached the phase of expanding MDRTB control as a com-
ponent of a comprehensive TB control program, which is
described in the WHO guidelines for the treatment of TB
(3), the new Stop TB Strategy (15), and in the new WHO
guidelines for the programmatic management of drug-
resistant tuberculosis (26). As countries are purchasing and
using second-line drugs, the likelihood of misuse and cre-
ation of strains of TB resistant to all known anti-TB drugs
increases. The GLC mechanism offers a way to provide
access to care while ensuring rational and effective use of
drugs. Beginning in 2002, the Global Fund to Fight AIDS,
Tuberculosis and Malaria (GFATM) mandated that
requests for second-line drugs for managing MDRTB
should go through GLC to prevent their misuse. The GLC
MDRTB Management in Resource-limited Settings
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Figure 2. Proportion of multidrug-resistant tuberculosis patients in
the 5 sites previously treated with first-line drugs only or with first-
and second-line drugs.model has been proposed to improve access to malaria (27)
and HIV/AIDS treatment (28,29). As of May 2006, a total
of 41 MDRTB control projects in 37 countries were
endorsed by GLC, and >21,000 MDRTB patients were
approved for treatment. The number of GLC-approved
MDRTB control programs is increasing rapidly, both as a
result of more funding for TB control from the GFATM
and mainstreaming of MDRTB management into general
TB control efforts. However, with the estimated incidence
of 424,203 MDRTB cases, most cases remain undiagnosed
and untreated. Expanding projects and accelerating evi-
dence gathering are necessary to further develop interna-
tional policies. The future success of MDRTB
management in resource-limited settings will depend on
the ability of the donor community and technical agencies,
as well as TB-endemic countries themselves, to expand
and strengthen MDRTB control programs.
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